Information Provided By: 
Fly News Breaks for October 4, 2016
ACRX
Oct 4, 2016 | 07:32 EDT
Jefferies analyst Hugo Ong says his firm's first Emergency Department physician survey on trends for acute pain management suggests a positive outlook for AcelRx's ARX-04. Physicians expect to use the drug, which could be available by the end of 2017, in 19% of their patients with moderate pain and 27% with severe pain in 2018, Ong tells investors in a research note. He believes the survey bodes well for ARX-04 and reiterates a Buy rating on AcelRx with a $7 price target.
News For ACRX From the Last 2 Days
There are no results for your query ACRX
